SHORT REPORT

Idiopathic intracranial hypertension and anticyclodiulin antibodies

A Kesler, M H Ellis, T Reshef, E Kott, N Gadoth

Abstract
The association of idiopathic intracranial hypertension (IIH) or pseudotumour cerebri (PTC) with anticyclodiulin antibodies (aCL-Abs) has been only acknowledged recently. However, its true incidence is as yet unknown.

In this retrospective study, the co-occurrence of IIH and aCL-Abs was looked for among a relatively large group of patients diagnosed with IIH or PTC in the neuro-ophthalmology clinic during the years of 1992–8. All patients underwent routine blood tests and the presence of activated protein C resistance and protein S and protein C deficiency were recorded. ACL-Abs were determined in all patients. The co-occurrence of IIH and aCL-Abs was found in three out of 37 patients (8.1%), which is higher than the incidence of aCL-Abs in the general population but considerably lower than that reported in two previously published studies. The aCL-Ab positive patients in our series were significantly older and thinner than those in whom antibodies were undetected. In conclusion, it seems that patients with this association should be considered as a unique subgroup of IIH.

Keywords: intracranial hypertension; anticyclodiulin antibodies; pseudotumour cerebri

Idiopathic intracranial hypertension (IIH), also known as pseudotumour cerebri (PTC) is the term used to describe the occurrence of raised intracranial pressure which is not due to mass lesions, obstruction of CSF flow, or focal structural abnormalities, in alert and oriented patients. Headaches, transient visual obscurations, tinnitus, and horizontal diplopia. Relevant cerebral sinus thrombosis and intracranial mass lesions or obstruction of the ventricular system were excluded in all patients using contrast enhanced brain CT and MRI. No patient underwent angiography as all had a typical clinical picture of IIH. The laboratory investigation included complete blood count, routine biochemical profile (SMA 16), determination of activated protein C resistance (APCR), protein C activity, protein S antigen (free) concentration and activity, and antithrombin activity.

Activated protein C resistance was determined using a partial thromboplastin time (PTT) based test in which the results of the PTT test were compared before and after the addition of activated protein C to the test reaction (Chromogenix, Sweden). Protein C activity was measured using a chromogenic assay (Dade, USA). Protein S activity was measured using protein S deficient plasma with the addition of Ca2+ (Biopool, USA). Protein S free antigen was determined by enzyme linked immunosorbent assay (ELISA; Stago, France). Antithrombin III activity was measured using a chromogenic assay (Chromogenix, Sweden). Anticyclodiulin IgG and IgM antibodies were determined by a semiquantitative ELISA assay (Reads, USA).

When aCL-Abs were detected, the test was repeated after 6 weeks. A patient was regarded as aCL-Ab positive if he had at least two positive tests.

Obesity was defined as a body mass index $>30$ kg/m$^2$. However, 3%–5% of healthy people may have circulating anticyclodiulin antibodies without having an increased risk for thromboembolism.

The purpose of this study was to determine the prevalence of aCL-Abs in a group of patients with IIH.

Patients and methods
The medical records of all patients diagnosed with IIH or PTC between the years 1992 and 1998 were reviewed. There were 41 patients in whom aCL-Abs were determined. Four of these (two with aCL-Abs) had cerebral sinus thrombosis and were excluded. Thus the study population consisted of 37 patients in whom the association of IIH and aCL-Abs was looked for.

All reported at least one of the following symptoms: headaches, transient visual obscurations, tinnitus, and horizontal diplopia. Relevant cerebral sinus thrombosis and intracranial mass lesions or obstruction of the ventricular system were excluded in all patients using contrast enhanced brain CT and MRI. No patient underwent angiography as all had a typical clinical picture of IIH. The laboratory investigation included complete blood count, routine biochemical profile (SMA 16), determination of activated protein C resistance (APCR), protein C activity, protein S antigen (free) concentration and activity, and antithrombin activity.

Activated protein C resistance was determined using a partial thromboplastin time (PTT) based test in which the results of the PTT test were compared before and after the addition of activated protein C to the test reaction (Chromogenix, Sweden). Protein C activity was measured using a chromogenic assay (Dade, USA). Protein S activity was measured using protein S deficient plasma with the addition of Ca2+ (Biopool, USA). Protein S free antigen was determined by enzyme linked immunosorbent assay (ELISA; Stago, France). Antithrombin III activity was measured using a chromogenic assay (Chromogenix, Sweden). Anticyclodiulin IgG and IgM antibodies were determined by a semiquantitative ELISA assay (Reads, USA).

When aCL-Abs were detected, the test was repeated after 6 weeks. A patient was regarded as aCL-Ab positive if he had at least two positive tests.

Obesity was defined as a body mass index $>30$ kg/m$^2$. However, 3%–5% of healthy people may have circulating anticyclodiulin antibodies without having an increased risk for thromboembolism.

The purpose of this study was to determine the prevalence of aCL-Abs in a group of patients with IIH.

Patients and methods
The medical records of all patients diagnosed with IIH or PTC between the years 1992 and 1998 were reviewed. There were 41 patients in whom aCL-Abs were determined. Four of these (two with aCL-Abs) had cerebral sinus thrombosis and were excluded. Thus the study population consisted of 37 patients in whom the association of IIH and aCL-Abs was looked for. All reported at least one of the following symptoms: headaches, transient visual obscurations, tinnitus, and horizontal diplopia. Relevant cerebral sinus thrombosis and intracranial mass lesions or obstruction of the ventricular system were excluded in all patients using contrast enhanced brain CT and MRI. No patient underwent angiography as all had a typical clinical picture of IIH. The laboratory investigation included complete blood count, routine biochemical profile (SMA 16), determination of activated protein C resistance (APCR), protein C activity, protein S antigen (free) concentration and activity, and antithrombin activity.

Activated protein C resistance was determined using a partial thromboplastin time (PTT) based test in which the results of the PTT test were compared before and after the addition of activated protein C to the test reaction (Chromogenix, Sweden). Protein C activity was measured using a chromogenic assay (Dade, USA). Protein S activity was measured using protein S deficient plasma with the addition of Ca2+ (Biopool, USA). Protein S free antigen was determined by enzyme linked immunosorbent assay (ELISA; Stago, France). Antithrombin III activity was measured using a chromogenic assay (Chromogenix, Sweden). Anticyclodiulin IgG and IgM antibodies were determined by a semiquantitative ELISA assay (Reads, USA).

When aCL-Abs were detected, the test was repeated after 6 weeks. A patient was regarded as aCL-Ab positive if he had at least two positive tests.

Obesity was defined as a body mass index $>30$ kg/m$^2$. However, 3%–5% of healthy people may have circulating anticyclodiulin antibodies without having an increased risk for thromboembolism.
Table 1 Demographic, clinical, and laboratory data on 37 patients with IIH

<table>
<thead>
<tr>
<th>aCL-Ab</th>
<th></th>
<th></th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>Negative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients</td>
<td>3</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>Mean age (SD in y)</td>
<td>43.33 (6.3)</td>
<td>32.23 (8.5)</td>
<td>&lt;0.035</td>
</tr>
<tr>
<td>No of women (%)</td>
<td>3 (100)</td>
<td>32 (94.1)</td>
<td></td>
</tr>
<tr>
<td>Overweight (%)</td>
<td>None</td>
<td>28 (82.35)</td>
<td></td>
</tr>
<tr>
<td>Use of tetracyclines</td>
<td>None</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Polycystic ovaries</td>
<td>None</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>APCR</td>
<td>1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Essential thrombocytosis</td>
<td>None</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

APCR=activated protein C resistance.

Table 2 aCL-Ab titres in three “positive” patients

<table>
<thead>
<tr>
<th>aCL-Ab titre</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>IgG units</td>
<td>IgM units</td>
</tr>
<tr>
<td>1</td>
<td>47</td>
<td>81.7; 48</td>
</tr>
<tr>
<td>2</td>
<td>47</td>
<td>34.1; 67</td>
</tr>
<tr>
<td>3</td>
<td>36</td>
<td>30.4; 30.3</td>
</tr>
</tbody>
</table>

Normal values: IgG <23; IgM 11.0

Results

Of the 37 patients, 35 were women (94.5%) and two were men (5.5%). The mean age of the group at diagnosis was 33.78 (SD 7.8) years (range: 19–48). The mean age of the women was 33.71 (SD 7.17) years and the men 23 (SD 5.6) years. In all patients, papilloedema was evident. The neurological examination was normal except for transient abducens palsy in those with horizontal diplopia.

Demographic, clinical, and laboratory data are shown in table 1.

Three women were aCL-Ab positive; one of them also had an APCR of 1.6 (normal >2). The aCL-Ab were of the IgG type whereas IgM type antibodies were undetected (table 2). Of the 34 aCL-Ab negative patients, one woman had an APCR of 1.8 (normal >2) and another essential thrombocytosis. Known risk factors for IIH were present only in the aCL-Ab negative patients. These included use of tetracyclines in four, polycystic ovaries in two, and use of growth hormone (hGH) in one.

Thirty of the 34 aCL-Ab negative patients, one woman and three aCL-Ab positive older women with normal weight. As expected, the “negative” patients had known risk factors for IIH such as the use of tetracyclines, hGH, and polycystic ovaries. The aCL-Ab positive patients were significantly overweight (88.23%) whereas all three “positives” had a normal body mass index.

Israeli prevalence of anticardiolipin antibodies was 3%–5%; APCR 5%–8%; protein C deficiency <1%; protein S deficiency <1%, among the normal general population from the present study patients were taken. The aCL-Ab positive patients were significantly older than the negatives (43.33 (SD 6.3) vs 32.23 (SD 8.5) years, p<0.035). All patients, regardless of the presence of aCL-Ab, were treated with daily acetylsalicylate, with no patient receiving anticoagulants. All experienced a rapid subjective improvement in headaches. During the long term follow up the papilloedema resolved and no permanent visual loss was encountered.

Discussion

In this retrospective study of a relatively large group of patients, the incidence of the association of IIH and IgG type aCL-Ab was lower than previously reported. Leker et al found this association in six out of 14 patients with IIH (42.85%). However, known risk factors for IIH such as thyroid disorders, Cush-}

Idiopathic intracranial hypertension and anticardiolipin antibodies

A Kesler, M H Ellis, T Reshef, E Kott and N Gadoth

J Neurol Neurosurg Psychiatry 2000 68: 379-380
doi: 10.1136/jnnp.68.3.379

Updated information and services can be found at:
http://jnnp.bmj.com/content/68/3/379

These include:

References
This article cites 13 articles, 3 of which you can access for free at:
http://jnnp.bmj.com/content/68/3/379#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Hypertension (380)
Immunology (including allergy) (1943)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/